COVID-19 mAb development pipeline

Abwiz Bio's Response to COVID-19

Abwiz Bio is open for business during the COVID-19 outbreak and is actively developing next-generation SARS-CoV-2 monoclonal antibodies for immediate diagnostic use.

Our antibody reagents are available for purchase and immediate preparation/shipping under strict clean and sterile conditions. We are continuing to support basic and translational research with our academic and corporate partners during this time, and our revolutionary rabbit mAb development platform and affinity maturation services are ready to advance your goals.

Learn more about all that we are doing, and get updates on our current progress developing SARS-CoV-2 mAbs.

Abwiz Bio has been awarded a STTR grant from the NIH! We will develop an antibody to treat rheumatoid arthritis.

High-quality phospho-specific monocolonal antibodies for flow cytometry

High-quality phospho-specific
monoclonal antibodies for flow cytometry

Explore Phospho Antibodies

Phospho Antibodies

Rabbit Monoclonal Antibody Development

Antibody Affinity Maturation

Cell-based Phage Panning

The Abwiz Bio
Difference

Our patented WizAmp™ amplification procedure (US 9,890,414) creates rabbit phage display antibody libraries with larger diversity and higher quality compared to any other available methods.
Our highly-engineered, proprietary vector expresses native rabbit Fabs in E. coli without modification, solving a well-known toxicity problem.

Explore Our Technology